GlassScriptPhysician profile
Wendy K Howard
NPI 1326170952
$2,460.91
in general payments reported to CMS, 2019-2025
13 companies · $530 in 2025
The $530 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $293 · 2022: $236 · 2023: $823 · 2024: $578 · 2025: $530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,932.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,931.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $540.42 | 2021-2025 | Xtampza, Belbuca |
| Boston Scientific Corporation | $484.52 | 2021-2025 | General - Pain Management, Intracept Rf Probe |
| Scilex Pharmaceuticals INC. | $406.02 | 2021-2025 | Ztlido |
| Nevro Corp. | $320.90 | 2021-2024 | Senza |
| Saluda Medical Americas, INC. | $254.13 | 2023-2025 | Evoke, Evoke Scs |
| Medtronic, INC. | $110.02 | 2021-2025 | Inceptiv, Intellis Adaptivestim, Synchromedii |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $102.99 | 2021-2024 | Relistor |
| Spr Therapeutics, INC | $85.03 | 2022-2025 | Sprint Pns System |
| Vertex Pharmaceuticals Incorporated | $51.07 | 2024-2025 | |
| Abbvie INC. | $34.99 | 2024 | |
| Nalu Medical, INC. | $30.24 | 2022-2023 | Nalu Neurostimulation System |
| Si-Bone, INC. | $24.99 | 2024 | |
| Grt US Holding, INC. | $15.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wendy Howard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.